Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT04566991

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Aditya S. Pandey, MD (from the registry)
Registry
  • NCT NCT04566991
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04566991. Randomized; double masking; primary purpose treatment. Start 2022-03-20 (actual); primary completion 2029-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Acronym
DISH
Condition
Aneurysmal Subarachnoid Hemorrhage
Intervention (Drug)
Deferoxamine
Intervention (Drug)
Placebo
Lead sponsor
Aditya S. Pandey, MD (class: other)

Record details

Record id
cardio:ct-nct04566991
Content hash
846fcbaf43731613b88b450a6e7a449df3d133e02e0048a5fc6ddf5e2b1848ad